75 related articles for article (PubMed ID: 348310)
1. Phase I study of maytansine using a 3-day schedule.
Cabanillas F; Rodriguez V; Hall SW; Burgess MA; Bodey GP; Freireich EJ
Cancer Treat Rep; 1978 Mar; 62(3):425-8. PubMed ID: 348310
[TBL] [Abstract][Full Text] [Related]
2. Maytansine: a phase I study of an ansa macrolide with antitumor activity.
Blum RH; Kahlert T
Cancer Treat Rep; 1978 Mar; 62(3):435-8. PubMed ID: 348312
[TBL] [Abstract][Full Text] [Related]
3. Initial clinical trials of maytansine, an antitumor plant alkaloid.
Chabner BA; Levine AS; Johnson BL; Young RC
Cancer Treat Rep; 1978 Mar; 62(3):429-33. PubMed ID: 348311
[TBL] [Abstract][Full Text] [Related]
4. Results of a phase II study of maytansine in patients with breast carcinoma and melanoma.
Cabanillas F; Bodey GP; Burgess MA; Freireich EJ
Cancer Treat Rep; 1979 Mar; 63(3):507-9. PubMed ID: 371803
[TBL] [Abstract][Full Text] [Related]
5. A therapeutic trial of maytansine.
Blum RH; Wittenberg BK; Canellos GP; Mayer RJ; Skarin AT; Henderson IC; Parker LM; Frei E
Cancer Clin Trials; 1978; 1(2):113-7. PubMed ID: 757139
[TBL] [Abstract][Full Text] [Related]
6. Minimal single-agent activity of maytansine in refractory breast cancer: a Southwest Oncology Group study.
Neidhart JA; Laufman LR; Vaughn C; McCracken JD
Cancer Treat Rep; 1980; 64(4-5):675-7. PubMed ID: 7427953
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]-(m-AMSA) using a single-dose schedule.
Von Hoff DD; Howser K; Gormley P; Bender RA; Glaubiger D; Levine AS; Young RC
Cancer Treat Rep; 1978 Oct; 62(10):1421-6. PubMed ID: 361222
[TBL] [Abstract][Full Text] [Related]
8. Phase II evaluation of maytansine in patients with advanced head and neck cancer.
Creagan ET; Fleming TR; Edmonson JH; Ingle JN
Cancer Treat Rep; 1979; 63(11-12):2061-2. PubMed ID: 526939
[No Abstract] [Full Text] [Related]
9. Phase II trial of maytansine in patients with advanced colorectal carcinoma.
O'Connell MJ; Shani A; Rubin J; Moertel CG
Cancer Treat Rep; 1978 Aug; 62(8):1237-8. PubMed ID: 356981
[No Abstract] [Full Text] [Related]
10. Phase I study of weekly maytansine given by iv bolus or 24-hour infusion.
Chahinian AP; Nogeire C; Ohnuma T; Greenberg ML; Sivak M; Jaffrey IS; Holland JF
Cancer Treat Rep; 1979; 63(11-12):1953-60. PubMed ID: 526928
[No Abstract] [Full Text] [Related]
11. Phase II trials of maytansine, low-dose chlorozotocin, and high-dose chlorozotocin as single agents against advanced measurable adenocarcinoma of the pancreas. Gastrointestinal Tumor Study Group.
Cancer Treat Rep; 1985 Apr; 69(4):417-20. PubMed ID: 2859924
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of maytansine in patients with advanced lymphomas: an Eastern Cooperative Oncology Group pilot study.
Rosenthal S; Harris DT; Horton J; Glick JH
Cancer Treat Rep; 1980; 64(10-11):1115-7. PubMed ID: 7459897
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of maytansine in advanced breast cancer.
Edmonson JH; Rubin J; Kvols LK; O'Connell MJ; Frytak S; Green SJ
Cancer Treat Rep; 1981; 65(5-6):536-7. PubMed ID: 7237478
[No Abstract] [Full Text] [Related]
14. Phase II evaluation of maytansine in patients with metastatic lung cancer.
Eagan RT; Creagan ET; Ingle JN; Frytak S; Rubin J
Cancer Treat Rep; 1978 Oct; 62(10):1577-9. PubMed ID: 709559
[No Abstract] [Full Text] [Related]
15. Early clinical study of an intermittent schedule for maytansine (NSC-153858): brief communication.
Eagan RT; Ingle JN; Rubin J; Frytak S; Moertel CG
J Natl Cancer Inst; 1978 Jan; 60(1):93-6. PubMed ID: 628025
[TBL] [Abstract][Full Text] [Related]
16. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of maytansine and chlorozotocin in patients with disseminated malignant melanoma.
Ahmann DL; Frytak S; Kvols LK; Hahn RG; Edmonson JH; Bisel HF; Creagan ET
Cancer Treat Rep; 1980; 64(4-5):721-3. PubMed ID: 6448689
[No Abstract] [Full Text] [Related]
18. Phase II study of maytansine in advanced sarcomas.
Edmonson JH; Hahn RG; Creagan ET; O'Connell MJ
Cancer Treat Rep; 1983 Apr; 67(4):401-2. PubMed ID: 6850657
[No Abstract] [Full Text] [Related]
19. Phase II study of maytansine in the treatment of advanced or recurrent squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study.
Thigpen JT; Ehrlich CE; Conroy J; Blessing JA
Am J Clin Oncol; 1983 Aug; 6(4):427-30. PubMed ID: 6869315
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of triglycidylurazol given on a 5-day i.v. schedule.
Nicaise C; Rozencweig M; Crespeigne N; Dodion P; Gerard B; Lambert M; Decoster G; Kenis Y
Cancer Treat Rep; 1986 May; 70(5):599-603. PubMed ID: 3708609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
